Abstract: The discovery of immune checkpoints and subsequent clinical development of checkpoint inhibitors have revolutionized the field of oncology. The durability of the antitumor immune responses has raised the hope for long-term patient survival and potential cure; however, currently, only a minority of patients respond. Combination strategies to help increase antigen release and T-cell priming, promote T-cell activation and homing, and improve the tumor immune microenvironment, all guided by predictive biomarkers, can help overcome the tumor immune-evasive mechanisms and maximize efficacy to ultimately benefit the majority of patients. Great challenges remain because of the complex underlying biology, unpredictable toxicity, and accurate assessment of response. Carefully designed clinical trials guided by translational studies of paired biopsies will be key to develop reliable predictive biomarkers to choose which patients would most likely benefit from each strategy.
O ver the past century, generations of tumor immunologists and clinicians have been exploring the possibility of harnessing the patient's own immune system to fight cancer. Some success had been obtained with cancer vaccines and high-dose cytokine therapy, but at a very low rate of response in a limited number of tumor types that are considered more immunogenic than others. Nonetheless, the durability of these responses, likely benefited from the memory of the adaptive immune system, inspired many to continue to study the mechanisms of immune escape by cancer. In the past decade, the clinical testing of immune checkpoint inhibition, especially the programmed cell death 1 (PD-1) checkpoint, has resulted in major breakthroughs in the development of modern immunotherapies with improved response rates in a variety of tumor types, most of which were previously considered immunotherapy nonresponsive.
Programmed cell death 1 receptor is expressed on the surface of T cells when activated through T-cell receptor (TCR) engagement. 1 Programmed cell death 1 ligand (PD-L1), on the other hand, can be expressed by tumor cells constitutively or in response to interferon (IFN)-induced signaling through the IFN receptor. When PD-L1 binds to PD-1, the T cell is deactivated and exhausted. This adaptive immune resistance appears to be a major immune-evading mechanism by many cancers, as PD-L1 expression is frequently upregulated on the surface of tumor cells, 2 and clinical development of PD-1/L1 inhibitors has led to consistent clinical benefit to patients with a variety of cancers. 3 Currently, 3 monoclonal antibodies blocking the PD-1/L1 checkpoint (pembrolizumab, nivolumab, and atezolimumab) have been approved by regulatory bodies for the treatment of metastatic melanoma, 4, 5 non-small cell lung cancer (NSCLC), 6, 7 renal cell carcinoma, 8 bladder cancer, 9 Hodgkin lymphoma, 10 head and neck squamous cell carcinoma, and have shown efficacy in many other different tumor types. Because the PD-1/L1 checkpoint occurs in the periphery at the effector phase of T-cell activation, the toxicity profile is very favorable, with less than 15% of patients experiencing severe adverse effects. More excitingly, a common feature of these checkpoint inhibitors is the plateau of the survival curves at the end of the tail, suggesting long-term disease control and the potential of a cure, which has been a hallmark of immunotherapy.
Despite the unprecedented durable response rates observed with PD-1/L1 blockade, several common cancer types have shown very low frequency of response (breast, prostate, colon, etc) and even for the responding tumor types, only 10% to 40% of treated patients usually benefit. The great challenge that the immunotherapy field is facing is to develop biomarkers to predict response, identify patients less likely to respond, and develop rational combination therapies to improve the outcomes. Because the PD-1/L1 checkpoint functions at the last step of effector T-cell activation, a reasonable approach would be to use PD-1/L1 inhibitors as the backbone of this combination. In this article, we reviewed the rationale and state of development of combination strategies to improve efficacy of anti-PD-1/L1 therapy, including increase in tumor-specific antigen release and presentation, enhancement of T-cell priming and homing to the tumors, augmentation of T-cell effector function, suppression of immune-suppressive cell populations (regulatory T cells [Tregs] , myeloid-derived suppressor cells [MDSCs] , macrophages), and cytokine release in the tumor microenvironment.
STRATEGIES TO INCREASE ANTIGEN RELEASE AND T-CELL PRIMING
It is important to understand that PD-1 checkpoint inhibitors rely on the host's immune system to mount the tumor-specific immune response that had been blocked at the last step of activation by the PD-1/L1 checkpoint. Therefore, strategies to increase tumor antigen release and presentation (chemotherapy, radiation therapy (RT), oncolytic viruses, Toll-like receptor [TLR] agonists, cancer vaccines) and T-cell priming (cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] checkpoint inhibitors) could rescue those patients who would otherwise not be able to mount this immune response and synergize with anti-PD-1/L1 checkpoint inhibitors.
The first step of antitumor immune response is the processing of the dying cancer cells by antigen-presenting cells (APCs), including dendritic cells (DCs). The maturation of APCs requires "danger" signals, 11 such as damage-associated molecular patterns (DAMPs), 12 recognized by innate pattern recognition receptors including TLR, RIG-I-like receptors, NOD-like receptors, and C-type lectin receptors. 13 The activated APCs then migrate to lymph nodes and present the tumor-specific peptides via major histocompatibility complex (MHC) class I or II molecules to CD4 and CD8 T cells with the corresponding TCRs.
CTLA-4 Checkpoint Inhibitors
Tumor antigen presentation by APCs to naive T cells and subsequent T-cell activation in the regional lymph nodes not only require antigen presentation machinery and sequence-specific TCRs, but also binding of costimulatory molecules (CD80 or CD86 on APCs and CD28 on T cells).
14 This triggers CTLA-4 expression on the activated T cells, which competitively binds to the CD80/ 86 and attenuates T-cell activation (Fig. 1) . Seminal work by Leach and colleagues 15 demonstrated the efficacy of anti-CTLA-4 antibody therapy in eradicating tumor growth in mouse models, which lead to the clinical development and approval in 2011 of the first immune checkpoint inhibitor ipilimumab, a fully human IgG1 antibody against CTLA-4, for treatment of advanced melanoma. Phase III clinical trials observed a low but durable response rate that was translated into significant overall survival benefit when compared with glycoprotein 100 (gp100) vaccine or chemotherapy alone. [16] [17] [18] Translational studies indicated that CTLA-4 blockade therapy can increase T-cell infiltration into the tumors regardless of clinical outcome 19 and broaden TCR repertoire in the peripheral blood. 20 However, it also induces tumor PD-L1 expression in the tumor microenviroment. This could explain why anti-CTLA-4 treatment alone is not effective in clinical testing of other tumor types, including NSCLC, bladder cancer, prostate cancer, gastric cancer, mesothelioma, and so on, 21, 22 and provides rationale for the combination of anti-CTLA-4 with anti-PD-1/ L1 inhibition.
The potential synergistic effect of combining inhibitors of the CTLA-4 and PD-1/L1 checkpoints is supported by testing in preclinical models. 23 The combination of ipilimumab and nivolumab was developed in patients with metastatic melanoma, and when compared with single-agent ipilimumab or single-agent nivolumab, it demonstrated a high response rate (~60%), increased number of complete responses, and significantly improved progression-free survival (PFS), [24] [25] [26] which led to the approval of this combination therapy in treating advanced melanoma in 2015. It needs to be noted that the trial was powered only to compare combination versus ipilimumab and nivolumab versus ipilimumab, but not combination versus nivolumab. Subgroup analysis suggests the benefit from combination therapy was mostly seen in the patients whose tumors were negative for PD-L1 staining. Nonetheless, the clinical benefit with the combination therapy is not without a cost, because more than half of the treated patients developed grade 3 or 4 treatment-related adverse events that are immune mediated in nature. Short-term follow-up studies suggested that treatment of immune-mediated adverse events with corticosteroids does not have impact on the outcome of the therapy, 27 and any-grade adverse events from nivolumab are associated with higher objective response rate (ORR) but not PFS. 28 However, longer-term patient follow-up and prospective studies are needed to confirm these observations. Combination of CTLA-4 and PD-1/L1 inhibitors has also been tested in NSCLC and other solid tumors, and different dose combinations and dosing schedules have been explored to improve tolerability and safety. A 39% ORR (and 39% stable disease) was observed with ipilimumab and nivolumab in metastatic renal cell carcinoma. 29 Early evidence of activity of ipilimumab plus nivolumab was also seen in patients with metastatic NSCLC. 30 When different dosing schedules were explored to combine pembrolizumab and ipilimumab (10 + 3 vs. 10 + 1 vs. 2 + 1) for patients with advanced NSCLC, 31 54% complete and partial response rates were observed across the dosing cohorts, with no compromised efficacy at the low-dose combinations. Another trial evaluated the combination of tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-L1) for patients with NSCLC. 32 Increased dosing of tremelimumab but not durvalumab is associated with increased toxicity, and 26% ORR was observed, including patients with PD-L1-negative tumors. Most recently, a phase I trial of frontline nivolumab monotherapy or combined with ipilimumab including decreased dose (1 mg/kg) and decreased dosing frequency (every 6 or 12 weeks) for patients with NSCLC 33 showed manageable treatment-related adverse events, and ORRs ranged from 13% to 39%, and efficacy was not affected by the decreased dose or frequency of ipilimumab. Responses were noted regardless of PD-L1 expression.
Radiation Therapy
Local cytotoxic therapies, such as RT, not only can increase tumor antigen release, but also can trigger the release of modulators of the innate immune response/DAMPs, such as type I IFN, calreticulin, ATP, and so on, which can activate DCs, and induce proinflammatory cytokines and chemokines, thus mediating a systemic antitumor immune response, the so-called abscopal effect. [34] [35] [36] [37] Evidence supports this in situ vaccination function of RT includes enhanced peptide repertoire and MHC class I expression, 38 increased tumor-specific antigen expression 39 and T-cell homing, 40 or improving the tumor microenvironment, 41 thus providing strong rationale to combine with immunotherapy.
Preclinical testing in immune-competent mouse models indicates potential synergy of RTwith both CTLA-4 42 and anti-PD-1/ L1 [43] [44] [45] checkpoint inhibitors, with efficacy demonstrated in both irradiated and nonirradiated tumors. Similar efficacy has been observed in case reports with concurrent RT and ipilimumab in patients with melanoma 37, 46 and NSCLC. 47 Although it was not clear whether the NSCLC case was a pure benefit of ipilimumab because the patient was naive to ipilimumab before the combination therapy, in the melanoma case, the patient had demonstrated disease progression on ipilimumab before RT was given and subsequently experienced significant tumor regression including the lesions not being irradiated. However, subsequent testing of this combination of local RT and systemic ipilimumab treatment for patients with castration-resistant prostate cancer (CRPC) did not show improved response when compared with ipilimumab alone in an early-phase trial 48 or survival benefit when compared with RT plus placebo in a phase III trial. 22 A series of 22 patients with advanced melanoma treated with radiation followed by 4 doses of systemic ipilimumab demonstrated slightly improved response (18% partial response and 18% stable disease) than historical data of ipilimumab. 44 Subsequent correlative studies and relevant mouse modeling showed up-regulation of PD-L1 in the resistant tumors, and addition of PD-1 blockade improved response in both treatment-naive tumors and the tumors that already demonstrated resistance to combination of RT and anti-CTLA-4 treatment. 49 It appeared that certain mode of RT, such as hypofractionated RT, is more effective than solitary-dose RT to induce immune response. 50 
Chemotherapy
The concept of combining chemotherapy with immunotherapy is seemingly counterintuitive because chemotherapy is commonly associated with marrow suppression and low white blood cell counts due to cytotoxicity to fast proliferating cells. However, preclinical and clinical data have suggested that there is rationale in support of this combination, 51 including increasing the release of antigens and DAMPs, reducing the number of MDSCs (gemcitabine), 52 depletion of circulating Tregs (cyclophosphamide), 53 and so on. In genetically engineered and orthotropic lung adenocarcinoma models, oxaliplatin and cyclophosphamide could successfully sensitize host antitumor T-cell immunity to immunecheckpoint blockade by direct drug actions on tumor cells, as well as innate immune response through TLR4 signaling and increased tumor infiltration of antitumor CD8 + T cells. 54 In a phase II randomized clinical trial of patients with advanced melanoma, combination of ipilimumab with dacarbazine showed higher response rate than treatment with ipilimumab alone. 55 Interestingly, the 2 partial responders (5.4%) in the ipilimumab monotherapy arm demonstrated durable response of more than 24 weeks and were ongoing at the end of the study. Five responses occurred in the ipilimumab plus dacarbazine group (14.3%), including 2 patients who achieved complete response that was durable and ongoing at the end of study, but the other 3 partial responders subsequently experienced progressive disease. In a randomized phase II trial for treatment-naive NSCLC patients, the different regimens were compared, carboplatin/paclitaxel alone with either placebo (control) or ipilimumab concurrently (4 doses of ipilimumab plus paclitaxel and carboplatin followed by 2 doses of placebo plus paclitaxel and carboplatin) or phased (2 doses of placebo plus paclitaxel and carboplatin followed by 4 doses of ipilimumab plus paclitaxel and carboplatin). 56 Interestingly, a small but significantly improved immune-related PFS (irPFS, primary endpoint) was observed with the phased ipilimumab regimen (delayed ipilimumab administration for 2 cycles) versus the control (5.7 vs. 4.6 months), but this was not observed with the concurrent ipilimumab (starting ipilimumab concurrently with chemotherapy cycles) (5.5 vs. 4.6 months). Similarly designed trials for treatment-naive, extensive-stage SCLC patients showed similar irPFS benefit in the phased-ipilimumab arm but not in the concurrentipilimumab arm. 57 These data suggest a potential benefit of having "induction chemotherapy" to initiate antigen release and immune response activation before combining with anti-CTLA-4.
Clinical testing of combination of chemotherapy with anti-PD-1/L1 therapy is ongoing in lung cancer and other tumor types that chemotherapy is standard of care. In NSCLC, frontline combinations of nivolumab with platinum-based chemotherapies demonstrated 43% of ORR but have been associated with increased toxicity of 47% grade 3 to 4 treatment-related adverse events. 58 When pembrolizumab was combined with either carboplatin/paclitaxel or carboplatin/pemetrexed, 30% and 58% of ORR was observed, whereas grade 3 to 4 toxicities were at 15% and 38%. 59 Lastly, when atezolizumab (anti-PD-L1) was combined with nab-paclitaxel for patients with metastatic triplenegative breast cancers, a 71% ORR was seen, but 56% of patients experienced grade 3 to 4 adverse events. 60 
Cancer Vaccines
Cancer vaccines have been explored for decades, with thousands of clinical trials being conducted with disappointing results, likely due to the subsequent immune checkpoints. Most solid tumors are poorly immunogenic, and cancer vaccines can enhance tumor antigen presentation and recognition. Therefore, cancer vaccines are a rational combination partner with checkpoint inhibitors. Strategies that have been investigated include tumor-specific peptides with or without adjuvants, DC or engineered cellular vaccines, live attenuated bacteria, and so on.
Peptide vaccines have been shown to induce peptide-specific immune responses. A modified tumor antigen gp100 vaccine increased the frequency of melanoma-specific CD8 cells in patients with advanced melanoma. 61 However, in a phase III clinical trial of patients with advanced melanoma, combination of gp100 peptide with ipilimumab did not improve the overall survival when compared with ipilimumab alone, 18 suggesting that checkpoints in the later phase of T-cell activation, such as PD-1/L1 checkpoint, might be more important. The selection of tumor antigen and number of tumor antigens that can induce tumor-specific immune response is still unclear. A phase I adjuvant trial for patients with advanced melanoma combining a multipeptide vaccine (gp100, NY-ESO-1, and MART-1) with nivolumab showed significant increases in MART-1, NY-ESO + , and gp100
+ T-cell populations in peripheral blood after 12 and 24 weeks of treatment with nivolumab and vaccine. 62 Conversely, another study has shown that tumor-specific T cells might be sequestered at the vaccination site, and antitumor immune response might be negatively influenced by certain vaccine preparations. 63 Therefore, selection of appropriate vaccine preparations is vital. Most recently, with the advancement of whole-exome sequencing and prediction of "neoantigens," that is, peptides unique to a particular mutations in the patient's tumor versus normal tissue, combination of neoantigen vaccine and checkpoint inhibitors presented a promising new strategy to trigger specific antitumor immune responses.
Dendritic cell vaccines have also been extensively studied. The first and only approved DC vaccine is sipuleucel-T, which targets prostatic acid phosphatase and has been shown to improve OS in patients with metastatic CRPC but showed no impact on PFS or prostate-specific antigen (PSA) levels. 64 Sipuleucel-T combined with the androgen receptor inhibitor enzalutamide concurrently or sequentially has been investigated in patients with CRPC and results in objective radiological and PSA tumor marker responses. 65 Combination of peptide-antigen-loaded DCs or intratumoral injection of immature DCs with checkpoint inhibitors has been studied, and efficacy was noted in preclinical mouse models. [66] [67] [68] [69] When autologous DCs were pulsed with MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide and administered with a dose escalation of the CTLA-4-blocking antibody tremelimumab, of the 16 treated patients with advanced melanoma, 2 partial responses and 2 complete responses were observed, all melanoma-free between 2 and 4 years after study initiation, at the higher range of the expected response rate with either agent alone. 70 Another vaccination strategy is using genetically modified tumor cell vaccines, such as irradiated granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing allogeneic tumor cells (GVAX) that can provide tumor antigen, attract DC via GM-CSF, and stimulate and amplify DC cell maturation. 71 In preclinical mouse models, combination of GVAX with CTLA-4 [72] [73] [74] or PD-1 75, 76 or both 77 checkpoint inhibitors promoted tumor eradication and survival of the treated animals, with increased CD8 cell infiltration and CD8/Treg ratio in these tumors. 78 Early-phase clinical trial combining GVAX with ipilimumab for patients with CRPC has shown safety and clinical benefit (PSA response or stabilization). 79 Another study investigating the combination of GVAX with ipilimumab in 15 advanced pancreatic cancer patients also showed prolonged disease stabilization in 3 patients and declined tumor markers in 7 patients. 80 Bacterial vaccination is an alternative platform to induce antitumor immune responses, pioneered more than a century ago by surgeon William Coley (Coley's toxin) for patients with sarcoma. 81 Recently, live-attenuated Listeria monocytogenes vaccines encoding tumor-specific antigens have been developed, which naturally target DCs in vivo and stimulate both innate and adaptive cellular immunity and have shown efficacy in several animal models. 82 Combination therapy with checkpoint inhibitors is under clinical investigation, including a phase I trial for patients with human papillomavirus-positive cervical or head and neck cancer combining live attenuated Listeria encoding the human papillomavirus type 16 oncoprotein E7 (ADXS11-001) with durvalumab (anti-PD-L1) (NCT02291055), and another one combining live attenuated Listeria encoding PSA (ADXS31-142) with pembrolizumab for patients with advanced prostate cancer (NCT02325557). Most recently, a phase II trial combined GVAX with or without a liveattenuated L. monocytogenes-expressing mesothelin (CRS207) for patients with advanced pancreatic cancer demonstrated significant overall survival benefit (hazard ratio, 0.53; P = 0.02), 83 and further combination of GVAX/CRS207 with nivolumab is ongoing (NCT02243371). Other bacterial vaccine platform is also being developed. 84 
Oncolytic Virus
Oncolytic viruses are genetically engineered virus constructs that can replicate in the tumor cells and elicit antiviral immune response by the host in the local tumor microenvironment, and this interplay between the oncolytic virus and the immune system can be translated into virus-induced antitumor immune response. 85 The first approved agent of this class is talimogene laherparepvec (T-VEC), a modified oncolytic herpes simplex virus that encodes GM-CSF with tumor specificity. Intratumoral injection of T-VEC can promote tumor lysis, tumor antigen release and presentation, together with GM-CSF release, can attract DCs into the injected tumors and increase DC maturation and priming of T cells, thus stimulating a systemic tumor-specific immune response, providing a highly attractive combination approach with checkpoint inhibitors. OPTiM, a phase III trial of T-VEC versus GM-CSF in unresectable stage IIIB-IV melanoma improved the primary endpoint of durable response rate in the T-VEC arm (16% vs. 2%). 86 Early-phase study in patients with advanced melanoma combining T-VEC with ipilimumab indicated safety and tolerability of this combination with a seemingly improved response (50%) than would be expected with either drug alone. 87 A phase Ib/III study assessing the safety and efficacy of T-VEC plus pembrolizumab in unresected stage IIIB-IV melanoma is ongoing, 88, 89 and the phase Ib result was reported at the 2016 American Society of Clinical Oncology annual meeting. Of the 21 enrolled patients, confirmed/not yet confirmed ORR per immune-related response rate was 48%/57%; complete response rate was 14%/24%. A follow-up randomized double-blind phase III phase is underway.
Other oncolytic viruses that have been tested include intratumoral injection of coxsackievirus A21 in patients with unresectable stage IIIC-IV M1c melanoma, 90 with reported 35% of irPFS at 6 months and best ORR per immune-related response rate of 24%. Combination of local injection of Newcastle disease virus with systemic CTLA-4 checkpoint blockade has shown promising results in preclinical models of melanoma. 91 Additional modified viral vectors that have been tested in combination with CTLA-4 blockade or other immune-modulatory agents and shown safety and efficacy in preclinical models and phase I trials include attenuated poxvirus vaccine targeting mutated p53, 92 recombinant adenoviral vector expressing human Her-2/neu antigen, 93 recombinant vaccinia and avipox viruses expressing carcinoembryonic antigen, and 3 T-cell costimulatory molecules (B7.1, ICAM-1, and LFA-3) (carcinoembryonic antigen-TRICOM), 94 as well as poxviral-based vector encoding PSA and 3 T-cell costimulatory molecules (CD58, CD80, and ICAM1) (PSA-TRICOM). 95 
Toll-Like Receptor Agonists
Toll-like receptors are a part of the innate immune system and are expressed on a wide range of immune cells, including monocytes, DCs, macrophages, and so on. 96, 97 These innate immune cells have a critical role in the defense against infection and disease (including cancer), and TLRs are pattern recognition receptors to detect pathogen-associated patterns and danger-associated patterns. Activation of TLRs on DC triggers maturation of the APC, induction of inflammatory cytokines, and the subsequent priming of naive T cells for adaptive immunity. Therefore, it is rational to harness agonists of TLR signaling as vaccine adjuvants to enhance the induction of vaccine-specific responses against cancer. However, some TLRs, such as TLR2, TLR4, and TLR7, have been shown to promote tumor growth or chemotherapy resistance. [98] [99] [100] Therefore, careful selection of the subtype of TLR for activation and the specificity of activation are critical. In a mouse model of melanoma, TLR3 activation was shown to induce type I IFN and increase tumor-infiltrating lymphocytes (TILs) and synergize with anti-PD-1 therapy. 101 Toll-like receptor 9 agonists could also increase T-cell infiltration in the CT26 colon adenocarcinoma mouse model, 102 indicating that this subtype of TLR agonists might be combined with checkpoint inhibitors. In a lymphoma mouse model, the combination of anti-OX40 and anti-CTLA-4, as well as intratumoral CpG (a TLR9 agonist), induced antitumor CD4 and CD8 T-cell immunity and cured large and systemic lymphoma tumors without chemotherapy. 103 In another bladder cancer mouse model, intratumoral injection of CpG with anti-CTLA-4 or anti-PD-1 increased the survival of mice, with anti-PD-1 plus CpG being superior to either agent alone. The combination increased the number of circulating tumor-specific CD107a-expressing CD8 T cells and activated (CD25FoxP3 − ) CD4 splenocytes, as well as decreased numbers of Tregs in the tumors. 104 A phase I study combining TLR9 (PF-3512676) with tremelimumab showed 2 (of 17) melanoma patients with partial responses, but with increased toxicity (2 dose-limiting toxicities that required steroids). 72 There are several phase I clinical trials ongoing testing the combination of TLR9 agonist with anti-PD-1 therapy.
STRATEGIES TO PROMOTE T-CELL ACTIVATION AND HOMING
Following priming and activation in the lymph nodes, T cells migrate via the systemic vasculature to the tumors, facilitated by the adhesion molecules on the endothelium for extravasation, and recognize and eradicate the tumor targets via interaction of TCR and tumor antigen presented by the MHC molecules. There are multiple costimulatory or coinhibitory receptors on activated T cells to regulate the activation, differentiation, function, and survival of the T cells, 105 which can be hijacked by the tumors to evade immune surveillance. But they also provide rationale for the development of effective immune-modulatory agents by targeting these receptors, the majority of which belong to either the immunoglobulin superfamily (CD28, ICOS, CTLA-4, PD-1, lymphocyteactivating gene 3 [LAG3], TIM3 [T-cell immunoglobulin domain and mucin domain 3], BTLA, VISTA, CD160, etc) or the tumor necrosis factor receptor superfamily such as GITR, OX40, 4-1BB/ CD137, CD40, CD30, and so on. 14 Agonists of T-cell costimulation (4-1BB, OX40, CD40, GITR, and ICOS) can amplify T-cell activation and enhance antitumor immune responses, thus providing strong rationale to be combined with checkpoint inhibitors. 106 
4-1BB/CD137 Agonists

4-1BB/CD137 receptor is a costimulatory receptor found on both T cells and natural killer (NK) cells, as well as DCs and myeloid cells, and when activated could improve T-cell function and survival, as well as regulate Treg function. 4-1BB/CD137
-deficient mice showed enhanced T-cell proliferation, but cytokine production and cytotoxic T-cell activity were diminished. Interestingly, 4-1BB/ CD137 deletion also led to an increase in myeloid progenitor cells in the periphery (blood, bone marrow, and spleen). 107 Tumorreactive TILs from freshly resected ovarian and melanoma tumors naturally express higher levels of CD137 than circulating T cells. CD137 + TILs also mediated superior antitumor effects in vivo, compared with CD137 − TILs. 108 In mouse models, combination of 4-1BB/CD137 agonists with checkpoint inhibitors showed beneficial effects, including with CTLA-4 blockade in MC38 colon carcinoma 109 and GL261 glioblastoma, 110 but not in B16 melanoma tumors, and with PD-1/L1 checkpoint inhibitors in colon carcinoma, B16F10 melanoma, and ID8 ovarian carcinoma, [111] [112] [113] with the highest efficacy observed with triple therapy (CD137 agonist and blockade of both PD-1 and CTLA-4). 111 A recent study in mouse models of colon carcinoma (MC38) and melanoma (B16F10) showed a critical need for BATF3-dependent DCs in cross-priming of tumor antigens to CTLs that subsequently upregulate PD-1 and CD137 and are crucial to the efficacy of immunostimulatory antibodies. 114 Two 4-1BB agonists are leading the clinical developments, urelumab and utomilumab, with single agent and combination therapies being evaluated. Urelumab was evaluated in a phase I study of 83 patients with advanced melanoma, renal cell carcinoma, ovarian cancer, and prostate cancer, 115 with clinical activity seen across dose ranges and tumor types. A phase II trial of urelumab, however, was temporarily suspended because of high incidences of hepatotoxicity. 116 Phase I trial of utomilumab showed no significant toxicity, with evidence of clinical activity seen in 9 of 24 patients. 117 Multiple clinical trials are ongoing to evaluate the combination of 4-1BB/CD137 agonists with PD-1/ L1 checkpoint inhibitors (NCT02179918).
A study in mouse models also suggests a potential synergistic effect of 4-1BB/CD137 agonists with antibodies that cause antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells and up-regulate 4-1BB on the NK cells. 118 Activation of CD137 enhances NK cell degranulation and cytotoxicity. Combination of anti-CD137 with HER-2 119 or CD20 120 antibodies potentiated their antibody-dependent cytotoxicity. Clinical trials are ongoing testing the combination of anti-CD137 with rituximab, cetuximab, and elotuzumab (enhance NK cytotoxicity and ADCC).
121,122
OX40
OX40, also known as CD134, is found on T cells, NK cells, and neutrophils and is expressed transiently after T-cell activation and important in the survival of activated T cells and T-cell memory. 123 As OX40 is expressed only by activated T cells, it is rational to combine OX40 agonists with agents that increase T-cell activation. Preclinical mouse model studies have provided evidence of synergy for combination with 4-IBB agonists, 124 anti-PD-1, 125 and anti-CTLA-4 126 antibodies. In a phase I study with advanced solid tumors, anti-OX40 antibody treatment showed an acceptable toxicity profile and regression of at least 1 metastatic lesion in 12 of 30 patients, with upregulated markers of immune activation in peripheral blood and increased antitumor reactivity of T and B cells. 127 Several anti-OX40 antibodies are currently being developed either as single agent or in combination with CD137 agonist, anti-CTLA-4, and anti-PD-1/L1 antibodies.
CD40
CD40 is constitutively expressed on APCs and B cells, and its ligand CD40L is expressed on T cells. Activation of CD40 triggers APC maturation and expression of costimulatory stimulatory molecules that promotes T-cell activation.
14 In a genetically engineered mouse model of pancreatic cancer, an agonist CD40 antibody combined with gemcitabine chemotherapy demonstrated efficacy, and a further mechanistic study showed that tumor regression required macrophages but not T cells or gemcitabine.
128 CD40-activated macrophages rapidly infiltrated tumors, became tumoricidal, and facilitated the depletion of tumor stroma, suggesting a CD40-dependent mechanism for targeting tumor stroma. Phase I clinical trial of anti-CD40 (CP-870893) has been tested in combination with tremelimumab with 27.3% of ORR observed, but with significant toxicity including dose-limiting colitis and uveitis. 129 Induced PD-L1 expression was found in acquired resistance to anti-CD40 treatment, 130 providing rationale to combine with anti-PD-1/ L1 checkpoint inhibitors. Clinical trial testing combination of anti-CD40 and PD-1/L1 blockage is active or underway (NCT02706353).
T-Cell Exhaustion Markers (TIM3, LAG3)
Other checkpoint/coinhibitory molecules similar to PD-1 can be utilized by cancer cells to produce T-cell exhaustion and dampen T-cell activity. TIM3 is a receptor expressed on PD-1 + CD8 + exhausted TILs. TIM3 knockout mice do not develop overt autoimmune disease, but blockade of TIM3 can accelerate the development of autoimmunity. 131 Preclinical evidence of synergy of anti-TIM3 antibody with PD-1 blockade and 4-1BB agonists has been observed. 131, 132 LAG3 is expressed on both CD4 and CD8 T cells and is important in regulating Treg function. Studies in preclinical models support the combinatorial effect of blocking LAG3 and PD-1. 133 Clinical trials of antibodies targeting TIM3 and LAG3 as single or combination therapy with checkpoint inhibitors are ongoing.
Targeted Therapy
Molecularly targeted therapies are small molecule drugs that target tumor-specific driver mutations or tumor-dependent growth factors. Although drug resistance is a frequent occurrence with targeted inhibitors, a subset of treated patients are long-term responders. 134, 135 There is increasing evidence that at least certain targeted agents exert antitumor function through immune modulation. This topic has been extensively discussed elsewhere. 136, 137 Briefly, targeted therapy can have "immunosensitization" effects on the different components of the immune system, including increased antigen release, presentation, and MHC expression; enhanced T-cell function and homing; and improved tumor microenvironment, suggesting a potentially synergistic benefit of combining targeted therapy and immunotherapy beyond the expected additive effect of two effective treatments. 138 The first phase I trial of the BRAF inhibitor vemurafenib and ipilimumab in advanced melanoma was closed early because of dose-limiting hepatotoxicity. 139 A separate trial involving ipilimumab and another BRAF inhibitor, dabrafenib, did not encounter hepatotoxicity (NCT01767454), suggesting a drug-specific process. However, the triple combination arm of dabrafenib, trametinib (MEK inhibitor), and ipilimumab was discontinued because of colon perforations. 140 Combination of BRAF plus/minus MEK inhibitors with PD-1/ L1 inhibitors is better tolerated, and currently, there are several clinical trials that are testing this combination and have shown encouraging results in treating metastatic melanoma.
STRATEGIES TO IMPROVE THE TUMOR MICROENVIRONMENT
The concept of cancer immunoediting introduced by Schreiber 141 and colleagues in 2001 hypothesized the dual role of the host immune system as both suppressor and facilitator of tumor growth and progression, supported by a study using carcinogeninduced sarcomas generated from both wild-type and RAG2 −/− mice (deficient of T, B, and NK cells) and subsequently implanted in wild-type or RAG2
−/− hosts. The tumor cells generated from wildtype mice grew progressively when implanted in both wild-type and RAG2
−/− hosts, and the tumors generated from RAG2 −/− mice also grew progressively in RAG2 −/− hosts, but nearly half of the tumors implanted in the immune-competent wild-type mice were rejected. These results indicated that tumors that arise from immune-competent hosts are less sensitive to immune attack and highlighted that the tumor microenvironment might play a role in this immune escape. 142 Multiple components of the tumor microenvironment have been reported to be involved in the development of immune resistance and immunoediting and can serve as targets to improve the local immune environment and increase tumor immunogenicity and therefore are good combination partners of the checkpoint inhibitors.
Indoleamine 2,3-Dioxygenase Inhibitor
Indoleamine 2,3-dioxygenase (IDO) is a cytosolic enzyme that catalyzes the breakdown of tryptophan to its metabolites. 143 IDO is widely overexpressed in tumor cells and myeloid lineage cells, which has been associated with poor prognosis. It is produced by tumor cells and MDSCs in response to inflammatory signals including IFN-γ. 144 Seminal work done by Munn et al. 145 in 1998 suggests IDO might mediate immunosuppression based on the preferential sensitivity of T cells to tryptophan deprivation. Subsequent studies provided evidence that IDO activity could suppress T cells and NK cells 146, 147 and was critical to support activity of FoxP3 + Tregs 148 and MDSCs. 149 Up-regulation of IDO in the tumor microenvironment was a possible mechanism of resistance to anti-CTLA-4 immunotherapy, and when an IDO inhibitor was combined with anti-CTLA-4 antibodies, it significantly enhanced the therapeutic efficacy in different animal tumor models and was associated with increased TILs. 150, 151 There are several IDO inhibitors in clinical development. The most advanced is epacadostat (INCB024360), a selective oral inhibitor of the IDO1 enzyme. Preliminary data from a phase I trial combining epacadostat and ipilimumab (anti-CTLA-4) in patients with metastatic melanoma 152 were well tolerated, with 23% of patients experiencing grade 3 adverse events, a disease control rate of 60% in immunotherapy-naive patients and 30% in patients who had received prior immunotherapy treatments, and ORR of 30%. 153 In a phase I trial of patients with advanced solid tumors, combination of epacadostat with pembrolizumab (anti-PD-1) was well tolerated and also showed promising activity. 154 Eighteen percent of patients had grade 3 or greater treatment-related adverse events, mostly rash (8%) and increased lipase (3%). Of 19 patients with treatment-naive advanced melanoma, a disease control rate of 74% and an ORR of 58% were observed. With a median follow-up of 42 weeks, all responses were confirmed and ongoing, and median PFS has not been reached. A randomized phase III trial testing the combination of pembrolizumab and epacadostat versus placebo is ongoing for treatment-naive advanced melanoma. Indoximod, a tryptophan analog, is another IDO inhibitor under development. Phase I testing of indoximod in 48 patients did not reach maximum tolerated dose at 2000 mg twice a day, and 5 patients showed stable disease at more than 6 months. 155 Combination with ipilimumab in patients with advanced melanoma was safe with no dose-limiting toxicities, 156 and a phase II study combining indoximod with ipilimumab or anti-PD-1 (pembrolizumab or nivolumab) is ongoing (NCT02073123). GDC-0919 is also an IDO1 inhibitor, and preliminary results from a phase I trial showed tolerable toxicity up to 800 mg twice a day with a 21-day-on/7-day-off schedule, and 44% of patients prolonged stable disease for more than 4 months. 157 
Colony-Stimulating Factor 1 Receptor Inhibitor
Tumor represents a chronic inflammatory microenvironment that can skew macrophages to an anti-inflammatory phenotype. Tumor-associated macrophages play a crucial role in promoting tumor progression and resistance to chemotherapy in several mouse models. 158, 159 High density of macrophages is associated with poor prognosis in patients with different cancer types. However, conflicting data exist for others with both positive and negative associations reported, 160, 161 possibly due to the heterogeneity of the analyzed tumor stages, analyses performed, and macrophage markers utilized (e.g., CD68 vs. CD163 vs. CD206). Interestingly, macrophages in human colorectal cancer have been found to be functionally and phenotypically antitumor. 162 Production of the C-C chemokine ligand 2 (CCL2) and/or colony-stimulating factor 1 (CSF-1) is necessary to recruit macrophages to the tumor site and sustain their numbers, 163 and there is growing interest in therapeutics targeting these ligands and/or their respective receptors in an effort to ablate the protumorigenic properties of macrophages. Indeed, antibodies targeting CSF-1 receptor (CSF-1R) have been shown in some preclinical models (pancreatic cancer, cervical cancer, and glioblastoma) to deplete immunosuppressive macrophages and increase the CD8/CD4 ratio in the tumors that led to improved outcome and synergy with chemotherapy, RT, antiangiogenic agents, adoptive cell transfer, and checkpoint inhibitors. 158 The immune suppression by macrophages in animal models relies on arginase and NOS activity, but in humans, this dependence is lacking. 164 Macrophages could directly suppress T-cell responses through PD-L1 in patients with hepatocellular carcinoma, 165 which provides additional rationale to combine CSF-1R inhibitors with PD-1/L1 checkpoint inhibitors. 166 Currently, there are several ongoing clinical trials to test this concept. Because macrophages are important in the homeostasis in the liver, hepatotoxicity can be a concern with single-agent CSF-1R inhibition or combination therapies. In addition, questions remain whether to deplete macrophages or promote antitumor polarization would be more relevant and effective in human cancers. Translational studies using patientderived samples would be key to answer these questions and guide the clinical design and management of toxicity.
TGF-β Inhibitor
Transforming growth factor β (TGF-β) is a cytokine that plays important roles in the tumor microenvironment including angiogenesis and immunosuppression by stimulating Tregs. 167 Increased level of TGF-β is associated with poor prognosis in multiple different tumor types. 168, 169 Preclinical models have shown synergy combining TGF-β receptor kinase inhibitor I with anti-CTLA-4 and inhibited tumor growth in a melanoma model (BRAFV600EPTEN −/− ) 170 or fractionated RT by enhancing T-cell priming. 41 Clinical trials testing the combination of the TGF-β inhibitor (galunisertib) 171 and PD-1/L1 checkpoint blockade (durvalumab or nivolumab) are ongoing in patients with metastatic pancreatic cancer (NCT02734160) and NSCLC, hepatocellular carcinoma, or glioblastoma (NCT02423343).
Adenosine Receptor Antagonist
Adenosine was shown to inhibit T-cell proliferation and cytotoxic function via the A2A receptor on T cells, 172 as well as promote metastasis via the A2B receptor on tumor cells. 173 In addition, CD73 is the enzyme that dephosphorylates adenosine monophosphate to form adenosine, thus also suppressing immune function and promoting tumor cell metastasis, 174 as well as stimulates angiogenesis. 175 High expression of CD73 is associated with poor prognosis in different cancer types. [176] [177] [178] CD73 is also a potential biomarker for anti-PD-1 therapy, with high expression limiting anti-PD-1 efficacy, which can be rescued by concomitant A2A blockade. 179 Both A2A receptor antagonists and anti-CD73 antibodies serve as attractive targets to improve the immune microenvironment. In preclinical models, the combination of an A2A receptor antagonist with anti-CTLA-4 or anti-PD-1 synergistically inhibited tumor growth in breast cancer (4T1) and melanoma (B16F10), [180] [181] [182] and the combination of anti-CD73 and anti-CTLA-4 or anti-PD-1 enhanced the antitumor activity in colon (MC38), prostate (RM-1), and breast cancer (4T1) models. 183 Currently, clinical trials are ongoing to test the safety and tolerability of combined A2A receptor antagonist (CPI-444) and anti-PD-L1 (atezolizumab) (NCT02655822) and the combination of anti-CD73 (MEDI9447) plus anti-PD-L1 (durvalumab) (NCT02503774) in patients with advanced solid cancer.
Chemokine Receptor Inhibitors
Myeloid-derived suppressor cells and Tregs traffic to the tumor using specific chemokine and chemokine receptors. For example, tumors secrete ligands CCL5, CCL7, and CXCL8; bind to their receptors CCR1 or CXCR2 expressed on subtypes of MDSCs 184 ; and attract MDSCs in the tumor microenvironment. Inhibitors of these chemokine receptors could abrogate immune evasion and improve antitumor T-cell responses. In a mouse model of breast cancer, combination of a CCR1 inhibitor (CCX9588) and PD-L1 inhibitor synergistically reduced the tumor burden, 185 and anti-CXCR2 plus anti-PD-1 improved survival in a rhabdomyosarcoma model.
184
CCR4 is highly expressed by Tregs in the blood and tumors, 186 and anti-CCR4 inhibits Treg recruitment, as well as promotes ADCC, further reducing the Treg population. 187 Therefore, anti-CCR4 represents an attractive target to combine with immunecheckpoint blockade. Currently, anti-CCR4 (mogamulizumab) in combination with nivolumab (NCT02705105), durvalumab (NCT02301130), and tremelimumab (NCT02301130) is being tested in the clinic in patients with advanced solid tumors.
CXCR4, a receptor for the chemokine CXCL12, has been shown to promote an immunosuppressive tumor microenvironment through several mechanisms including Treg localization.
188 CXCR4 inhibitors have shown antitumor synergy with anti-PD-1 therapies in preclinical models 189 and are in clinical development. The most advanced is ulocuplumab, being tested in combination with nivolumab (NCT02472977).
Epigenetic Modulation
Epigenetic modification changes gene expression or cellular phenotype without changing the DNA sequence, including DNA methylation, chromatin remodeling, and so on, which could lead to changed expressions of tumor suppressor genes and/or protooncogenes, as well as immune-related genes. 190, 191 Epigenetic silencing of immune-related genes is a feature of the cancer genome that impacts antigen processing and presentation by tumor cells, facilitates immune evasion, and modulates the tumor microenvironment, making it a promising therapeutic target and a candidate to combine with checkpoint inhibitors. 192 In preclinical models, histone deacetylase inhibitors can synergize with adoptive cell transfer therapy to treat B16 murine melanoma by increased MHC and tumor-associated antigen expression by tumor cells, a proliferative advantage and improved function of the adoptively transferred cells. 193 In a lymphoma model, hypomethylating agents have shown to restore gene expression and promote CD8 + T-cell infiltration into the tumor attributed to demethylation-induced CD80 expression on tumor cells. 194 When combined with anti-CTLA-4, synergistic effect was seen in a murine mammary carcinoma and mesothelioma models with high CD8 and CD4 T-cell tumor infiltration. 195 Both hypomethylating agents (AZA) and histone deacetylase inhibitors (entinostat) could improve treatment outcome when combined with anti-PD-1 and anti-CTLA-4 antibodies to eradicate modestly immunogenic CT26 colon adenocarcinoma or metastatic 4T1 mammary carcinoma by eliminating circulating and tumor-infiltrating granulocytic MDSCs. 196 Based on these results, clinical studies are ongoing to investigate the safety and efficacy of combination approaches with epigenetic modulation.
STRATEGIES TO ACTIVATE NK CELLS
Natural killer cells are part of the innate immune response system and can produce proinflammatory cytokines and kill cancer cells following nonspecific activation with cytokines (interleukin 12 , IL-15, and IL-18), antigens, or cytomegalovirus. In the past decade, it was recognized that NK cells can have immunological memory, and their antitumor responses may be enhanced long term. 197 Activated NK cells express killer-cell immunoglobulinlike receptors (KIRs), which serve as a checkpoint and inhibit the cytotoxic activity of NK cells after interaction with MHC-I on tumor cells. 198 It can be beneficial to block both PD-1 or CTLA-4 and KIR for the activation of both T and NK cells or for those patients with acquired intrinsic mutation in the IFN response pathway that renders the tumor cells resistant to T-cell attack. 199 Clinical trials are ongoing to test the combination of anti-KIR (lirilumab) and nivolumab (NCT01714739) or ipilimumab (NCT01750580) in patients with advanced solid tumors.
ENGINEERED T CELLS
For patients whose immune system has not been able to mount an effective antitumor response, adoptive T-cell transfer (ACT) therapy is another promising strategy to combine with checkpoint inhibitors. For the treatment of melanoma, ex vivo culture and expansion of TILs and reinfusion of the tumor-reactive cells into the patient resulted in 50% of ORRs and 22% of complete tumor regression. 200 Strategies to engineer peripheral T cells include to express chimeric antigen receptors to target surface tumor antigens (e.g., CD19) or full TCR to target cytoplasmic tumor antigens (such as MART-1 or NY-ESO-1). 201 However, there might be a lack of sufficient T-cell infiltration into the tumor, and an immunosuppressive tumor microenvironment may limit the T-cell function. 202 Combination with checkpoint inhibitors can help maximize effector function. Indeed, anti-PD-1/L1 or anti-CTLA-4 when used together with ACT could synergistically reduce tumor growth and increase long-term survival in the MC38 colon carcinoma and B16 melanoma mouse models, as well as in transgenic Her-2 mice treated by ACT of Her-2-specific chimeric antigen receptor T cells and systemic anti-PD-1. [203] [204] [205] Anti-PD-1 promoted the proliferation of T cells and their cytotoxic activity with increased IFN-γ production and chemokine up-regulation (e.g., CXCL10) that result in increased T-cell infiltration. Currently, the combination of ACT and anti-CTLA-4 or anti-PD-1/ L1 is studied in early-phase clinical trials.
Conclusions and Future Directions
After more than a century of persistent exploration to harness the immune system to fight cancer, great strikes have been made in the past decade in the field of cancer immunotherapy. Immunecheckpoint blockade and combinations with other immunemodulatory agents have shown durable responses with improved survival in an excitingly long list of tumor types. Neither all patients nor all tumor types would benefit from the treatment, and heterogeneous response has been seen even for the same patient, calling for individualized immune-checkpoint combination approaches guided by predictive biomarkers for the optimal outcome for a larger number of patients with a broader spectrum of tumor types. The available approved and experimental therapeutic options discussed in this review create therapeutic possibilities, but need to be guided by sound scientific rationale and preclinical studies, as well as carefully designed clinical trials for effective treatment and confirming safety, because some of the toxicities may not be apparent in preclinical studies. The endpoints to evaluate effectiveness of immunotherapy should also be carefully chosen, because the durability of the clinical benefit, the hallmark of immunotherapy, needs to be evaluated in addition to the traditional response rate per RECIST. Besides the pharmacokinetics, confirmation of pharmacodynamics by paired tumor biopsies is critical in early-phase clinical testing of combination immunotherapies, given the underlying complicated biology, to be able to elucidate the available data and make informed decisions for greatest effectiveness in the most suitable population of patients, with minimal toxicities. With further advancement of our understanding of tumor immune biology and accumulation of clinical experience, it is a matter of time before the power of the immune system can be fully harnessed to eradicate cancer.
